20/20 Biolabs Inc
20/20 Biolabs Inc is a healthcare equipment company that develops and commercializes advanced diagnostic and therapeutic solutions for the treatment of chronic diseases.
Business. 20/20 Biolabs Inc (NASDAQ: AIDX) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm primarily engages in the sale of healthcare equipment. Specific details regarding its operating segments and geographic presence are not available. The company is headquartered in the United States and is listed on the NASDAQ stock exchange.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
20/20 Biolabs Inc (NASDAQ: AIDX) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm primarily engages in the sale of healthcare equipment. Specific details regarding its operating segments and geographic presence are not available. The company is headquartered in the United States and is listed on the NASDAQ stock exchange.
20/20 Biolabs Inc has a market capitalization of $14.46 million and a market price of $1.38 per share, based on the latest valuation data. The company has no dilution risk in the near term, as the number of basic and diluted shares outstanding is identical at 10,480,089 shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and return metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided in the industry configuration. As a result, a direct comparison to cohort medians for profitability and returns cannot be made at this time.
20/20 Biolabs Inc does not disclose segment or geographic revenue breakdowns in the available data, so no analysis of revenue concentration or geographic exposure can be performed. The company's growth trajectory is also not quantifiable, as no outlook data or revenue history is available in the provided dataset.
The company's risk profile is limited to the observation that liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents. No dilution risk is currently indicated, as the number of basic and diluted shares is the same. No recent events, such as filings or transcripts, are available in the dataset to inform the company's current strategic or operational direction.
- 20/20 Biolabs Inc is a small-cap healthcare equipment company with a market capitalization of $14.46 million.
- The company has no dilution risk in the near term, as basic and diluted shares are equal.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
- No segment or geographic revenue breakdowns are available, limiting the ability to assess revenue concentration.
- No profitability metrics or industry-specific KPIs are available for comparison to cohort medians.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Operating Officer · Stock Option → Common StockAcquired 150 000 @ $1,88grant · 2026-04-02
- Chief Financial Officer · Stock Option → Common StockAcquired 100 000 @ $1,88grant · 2026-04-02
- Director, Chief Executive Officer, 10% owner · Stock Option → Common StockAcquired 352 936 @ $3,39grant · 2026-03-03
- Director · Series A-2 Preferred Stock → Common StockDisposed 7 700conversion · 2026-02-19
- Director · Series A Preferred Stock → Common StockDisposed 13 029conversion · 2026-02-19
- Director · Series A-2 Preferred Stock → Common StockDisposed 6 135conversion · 2026-02-19
- Director · Series A-2 Preferred Stock → Common StockDisposed 31conversion · 2026-02-19
- Director · Series A-2 Preferred Stock → Common StockDisposed 7 669conversion · 2026-02-19
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 20/20 Biolabs Inc Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Director · Common StockOther 7 669 · 2026-02-19
- Director · Common StockOther 13 029 · 2026-02-19
- Director · Common StockOther 6 135 · 2026-02-19
- Director · Common StockOther 31 · 2026-02-19
- Director · Common StockOther 7 700 · 2026-02-19
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Revenue (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
- Net margin (FY 2025-12-31): -182.8%Derived (calculated)
- Gross margin (FY 2025-12-31): 29.6%Derived (calculated)
- Return on equity (FY 2025-12-31): 19,447.7%Derived (calculated)
- Return on assets (FY 2025-12-31): -90.4%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.60xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): -216.21xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -42.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 3.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 34.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 34.5%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 67.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 32.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 26.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 41.3%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -53.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -101.3%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 15.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 99.9%Derived (calculated)
- Current liabilities (annual): USD 2.46MSEC XBRL filing
- Shares outstanding (annual): 5.44MSEC XBRL filing
- Current assets (annual): USD 1.47MSEC XBRL filing
- Cost of revenue (annual): USD 1.44MSEC XBRL filing
- Total operating expenses (annual): USD 3.94MSEC XBRL filing